Treat the following as community-derived hypotheses, not validated outcomes: Hypothesis 1 Plateau breaking past retatrutide monotherapy Community framing is that adding cagrilintide engages a receptor system retatrutide does not target, which could theoretically extend weight loss past a retatrutide-monotherapy plateau
SGLT2 inhibitors have proven efficacy in slowing chronic kidney disease progression, reducing albuminuria, and decreasing risk of end-stage renal disease
Whether this is due to retained pigmentation, familiarity with the process or individual biology is difficult to say, but its a common observation among experienced users
Slower digestion and lower postmeal sugar spikes (helpful for metabolic health broadly)
When L-carnitine is ingested before exercise it has also been shown to delay fatigue via increased nitric oxide production and delay discomfort
If you have an anxiety disorder, continuing your existing treatment is essential